company background image
CLGN

CollPlant Biotechnologies NasdaqGM:CLGN Stock Report

Last Price

US$9.87

Market Cap

US$109.4m

7D

11.7%

1Y

-47.2%

Updated

12 Aug, 2022

Data

Company Financials
CLGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CLGN Stock Overview

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe.

CollPlant Biotechnologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CollPlant Biotechnologies
Historical stock prices
Current Share PriceUS$9.87
52 Week HighUS$23.00
52 Week LowUS$6.51
Beta1.1
1 Month Change14.10%
3 Month Change21.10%
1 Year Change-47.22%
3 Year Change178.03%
5 Year Change38.04%
Change since IPO-46.55%

Recent News & Updates

Jul 22
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

CLGNUS BiotechsUS Market
7D11.7%1.2%1.3%
1Y-47.2%-23.0%-11.7%

Return vs Industry: CLGN underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: CLGN underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is CLGN's price volatile compared to industry and market?
CLGN volatility
CLGN Average Weekly Movement10.3%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CLGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: CLGN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200466Yehiel Talhttps://www.collplant.com

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds.

CollPlant Biotechnologies Fundamentals Summary

How do CollPlant Biotechnologies's earnings and revenue compare to its market cap?
CLGN fundamental statistics
Market CapUS$109.42m
Earnings (TTM)-US$13.75m
Revenue (TTM)US$1.21m

90.7x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLGN income statement (TTM)
RevenueUS$1.21m
Cost of RevenueUS$1.15m
Gross ProfitUS$57.00k
Other ExpensesUS$13.80m
Earnings-US$13.75m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.24
Gross Margin4.72%
Net Profit Margin-1,138.94%
Debt/Equity Ratio0%

How did CLGN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CLGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLGN?

Other financial metrics that can be useful for relative valuation.

CLGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue59.5x
Enterprise Value/EBITDA-5.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does CLGN's PB Ratio compare to its peers?

CLGN PB Ratio vs Peers
The above table shows the PB ratio for CLGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.7x
ORTX Orchard Therapeutics
0.5x11.6%US$76.3m
FBIO Fortress Biotech
1.8x62.8%US$136.4m
CUE Cue Biopharma
2x17.5%US$117.1m
ARDX Ardelyx
2.7x69.3%US$143.7m
CLGN CollPlant Biotechnologies
2.5xn/aUS$109.4m

Price-To-Book vs Peers: CLGN is expensive based on its Price-To-Book Ratio (2.5x) compared to the peer average (1.7x).


Price to Earnings Ratio vs Industry

How does CLGN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: CLGN is expensive based on its Price-To-Book Ratio (2.5x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is CLGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLGN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CLGN's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CLGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CLGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CLGN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is CollPlant Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CollPlant Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has CollPlant Biotechnologies performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


13.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CLGN is currently unprofitable.

Growing Profit Margin: CLGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLGN is unprofitable, but has reduced losses over the past 5 years at a rate of 13.7% per year.

Accelerating Growth: Unable to compare CLGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: CLGN has a negative Return on Equity (-31.82%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is CollPlant Biotechnologies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CLGN's short term assets ($42.6M) exceed its short term liabilities ($2.6M).

Long Term Liabilities: CLGN's short term assets ($42.6M) exceed its long term liabilities ($2.9M).


Debt to Equity History and Analysis

Debt Level: CLGN is debt free.

Reducing Debt: CLGN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CLGN has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 13.3% each year.


Discover healthy companies

Dividend

What is CollPlant Biotechnologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLGN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CLGN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.7yrs

Average management tenure


CEO

Yehiel Tal (70 yo)

12.58yrs

Tenure

US$1,199,000

Compensation

Mr. Yehiel Tal has been the Chief Executive Officer of CollPlant Biotechnologies Ltd. (formerly known as CollPlant Holdings Ltd.) since January 2010 and also serves as its Director since 2022. Mr. Tal Co-f...


CEO Compensation Analysis

Compensation vs Market: Yehiel's total compensation ($USD1.20M) is above average for companies of similar size in the US market ($USD763.69K).

Compensation vs Earnings: Yehiel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CLGN's management team is seasoned and experienced (8.7 years average tenure).


Board Members

Experienced Board: CLGN's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.8%.


Top Shareholders

Company Information

CollPlant Biotechnologies Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: CollPlant Biotechnologies Ltd.
  • Ticker: CLGN
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$109.424m
  • Shares outstanding: 11.09m
  • Website: https://www.collplant.com

Number of Employees


Location

  • CollPlant Biotechnologies Ltd.
  • Weizmann Science Park
  • 4 Oppenheimer
  • Rehovot
  • 7670104
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.